Clinical Trial

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Study acronym: ALEPRO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-05-12; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2023-12-06
Trial Details
NCT Number NCT05872204
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Collaborators: Kom Op Tegen Kanker, Eli Lilly and Company, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Conditions Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
Enrollment 100 participants
Start Date 2023-11-30
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-05